FDA Grants Orphan Drug Designation to Cellenkos' CK0804 Treg Therapy for Treatment of Myelofibrosis

-- CK0804 is a first in class, CXCR4hi Treg therapeutic designed to preferentially traffic towards its ligand CXCL12 over expressed in the bone marrow and spleen in myelofibrosis. -- CK0804 engages with antigen presenting cells within target tissues and undergoes in vivo proliferation to...

Read More